FibroBiologics (FBLG) Non-Current Assets (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Non-Current Assets of $2.1 million for Q2 2026, down 44.25% year-over-year from $3.7 million in Q2 2025, and down 31.45% on a QoQ basis from $3.0 million in Q1 2026.
FibroBiologics (FBLG) Non-Current Assets (2022 - 2026) Analysis & Trends
FibroBiologics has reported Non-Current Assets for 5 years, with the latest figure at $2.1 million in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $2.1 million, down 44.25% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.9 million (up 15.22% YoY), and the FY2025 annual result was $3.3 million, up 47.5% from the prior year.
- Non-Current Assets retreated to $2.1 million in Q2 2026, from $3.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $3.7 million in Q2 2025 and troughed at $2.1 million in Q2 2026.
- A 5-year average of $2.7 million and a median of $2.4 million in 2024 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2025, when Non-Current Assets surged 55.18%; it then tumbled 44.25% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $2.2 million in 2022, then grew by 18.51% to $2.6 million in 2023, then fell by 14.93% to $2.2 million in 2024, then soared by 47.5% to $3.3 million in 2025, then plunged by 36.42% to $2.1 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $2.1 million in Q2 2026, $3.0 million in Q1 2026, and $3.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.08 Mn |
| Mar 31, 2026 | 3.03 Mn |
| Dec 31, 2025 | 3.27 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Dec 31, 2022 | 2.20 Mn |